<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-title>Lipids in Health and Disease</journal-title><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-511X-3-26</article-id><article-id pub-id-type="pmid">15571629</article-id><article-id pub-id-type="doi">10.1186/1476-511X-3-26</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Strandhagen</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>elisabeth.strandhagen@hjl.gu.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>henrik.zetterberg@clinchem.gu.se</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Aires</surname><given-names>Nibia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nibia.aires@astrazeneca.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Palm&#x000e9;r</surname><given-names>Mona</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mona.palmer@vgregion.se</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Rymo</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lars.rymo@clinchem.gu.se</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>kaj.blennow@neuro.gu.se</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Thelle</surname><given-names>Dag S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dag.thelle@hjl.gu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>the Cardiovascular Institute, Department of Medicine, Sahlgrenska University Hospital/&#x000d6;stra, G&#x000f6;teborg, Sweden</aff><aff id="I2"><label>2</label>Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital/Sahlgrenska, G&#x000f6;teborg, Sweden</aff><aff id="I3"><label>3</label>Institute of Clinical Neuroscience, Department of Experimental Neuroscience, Sahlgrenska University Hospital/M&#x000f6;lndal, M&#x000f6;lndal, Sweden</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>30</day><month>11</month><year>2004</year></pub-date><volume>3</volume><fpage>26</fpage><lpage>26</lpage><ext-link ext-link-type="uri" xlink:href="http://www.lipidworld.com/content/3/1/26"/><history><date date-type="received"><day>4</day><month>11</month><year>2004</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Strandhagen et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Strandhagen et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Strandhagen Elisabeth elisabeth.strandhagen@hjl.gu.se </dc:author><dc:title> The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>Lipids in Health and Disease 3(1): 26-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-511X(2004)3:1&#x0003c;26&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-511X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The response of serum cholesterol to diet may be affected by the apolipoprotein E (<italic>APOE</italic>) &#x003b5;2/&#x003b5;3/&#x003b5;4 polymorphism, which also is a significant predictor of variation in the risk of coronary heart disease (CHD) and CHD death. Here, we test the hypothesis that the <italic>APOE </italic>polymorphism may modulate the cholesterol-raising effect of coffee.</p></sec><sec><title>Objective</title><p>We determined the effect of a coffee abstention period and a daily intake of 600 mL coffee on serum cholesterol and triglycerides with respect to the <italic>APOE </italic>polymorphism.</p></sec><sec><title>Design</title><p>121 healthy, non-smoking men (22%) and women (78%) aged 29&#x02013;65 years, took part in a study with four intervention periods: 1 and 3) a coffee free period of three weeks, 2 and 4) 600 mL coffee/day for four weeks.</p></sec><sec><title>Results</title><p><italic>APOE &#x003b5;</italic>2 positive individuals had significantly lower total cholesterol concentration at baseline (4.68 mmol/L and 5.28 mmol/L, respectively, p = 0.01), but the cholesterol-raising effect of coffee was not influenced significantly by <italic>APOE </italic>allele carrier status.</p></sec><sec><title>Conclusions</title><p>The <italic>APOE &#x003b5; </italic>2 allele is associated with lower serum cholesterol concentration. However, the <italic>APOE </italic>polymorphism does not seem to influence the cholesterol-raising effect of coffee.</p></sec></abstract><kwd-group><kwd>controlled study</kwd><kwd><italic>APOE </italic>polymorphism</kwd><kwd>serum lipids</kwd><kwd>filtered coffee</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Apolipoprotein E (apoE) is a structural component of triglyceride-rich lipoproteins, chylomicrons, very-low-density lipoproteins (VLDL), and high-density-lipoproteins (HDL) [<xref ref-type="bibr" rid="B1">1</xref>]. Variation in the <italic>APOE </italic>gene sequence results in the 3 common alleles (<italic>&#x003b5;2, &#x003b5;3 </italic>and <italic>&#x003b5;4</italic>), which can produce 6 different genotypes (&#x003b5;2/&#x003b5;2, &#x003b5;2/&#x003b5;3, &#x003b5;2/&#x003b5;4, &#x003b5;3/&#x003b5;3, &#x003b5;3/&#x003b5;4 and &#x003b5;4/&#x003b5;4). The <italic>&#x003b5;2, &#x003b5;3 </italic>and <italic>&#x003b5;4 </italic>alleles encode three distinct forms of apoE (E2, E3 and E4) and have approximate frequencies of 8%, 77%, and 15%, respectively, in white populations [<xref ref-type="bibr" rid="B2">2</xref>]. ApoE3 seems to be the normal isoform in all known functions, while apoE4 and apoE2 can each be dysfunctional [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. In most populations, individuals with the <italic>APOE &#x003b5;2 </italic>allele display lower levels of plasma cholesterol compared with individuals carrying the <italic>APOE &#x003b5;3 </italic>allele, whereas individuals with the <italic>APOE &#x003b5;4 </italic>allele show higher levels of plasma cholesterol, especially LDL-cholesterol [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Subjects with <italic>APOE </italic>&#x003b5;3/&#x003b5;4 and &#x003b5;4/&#x003b5;4 genotypes absorb cholesterol effectively and have higher non-fasting serum triglyceride values than &#x003b5;4 negative individuals [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. The allelic variation in the <italic>APOE </italic>gene is shown to be a significant predictor of variation in the risk of coronary heart disease (CHD) and CHD death [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>], but the results from an extensive prospective study showed no associations [<xref ref-type="bibr" rid="B11">11</xref>]. Both the MONICA Project [<xref ref-type="bibr" rid="B12">12</xref>] and the Scandinavian Simvastatin Survival Study [<xref ref-type="bibr" rid="B13">13</xref>] suggest an increased risk of CHD for individuals carrying the <italic>APOE </italic>&#x003b5;<italic>4 </italic>allele. The <italic>APOE </italic>&#x003b5;<italic>4 </italic>allele is also considered a strong risk factor for Alzheimer's disease [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>].</p><p>The serum cholesterol-raising effect of coffee is due to the diterpenes kahweol and cafestol [<xref ref-type="bibr" rid="B17">17</xref>]. Earlier studies have shown a cholesterol-raising effect mainly of unfiltered coffee, because a major part of the diterpenes is retained by a paper filter [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. A recent trial, however, indicates that filtered coffee has a more pronounced serum cholesterol-raising effect than previously anticipated [<xref ref-type="bibr" rid="B21">21</xref>]. This finding was further corroborated in a randomized intervention study, where we demonstrated a considerable cholesterol-raising effect of filtered coffee [<xref ref-type="bibr" rid="B22">22</xref>]. In the study two coffee abstention periods were associated with a significant decline in serum cholesterol of 0.22 and 0.36 mmol/L, respectively, while 600 mL filtered coffee a day during two different periods increased serum cholesterol by 0.25 and 0.15 mmol/L, respectively. Here, we test the hypothesis that these effects might be modulated by the <italic>APOE &#x003b5;2</italic>/<italic>&#x003b5;3</italic>/<italic>e4 </italic>polymorphism.</p></sec><sec><title>Subjects and methods</title><sec><title>Trial design</title><p>The study was organised as a prospective, controlled study with four consecutive trial periods. The first and third periods were 3 weeks of total coffee abstention. The second and fourth period consisted of 4 weeks with the subjects consuming 600 mL filter brewed coffee/day.</p><p>The main outcome or effect variable was total serum cholesterol and the effect was assessed as the difference between the measurements at the beginning and the end of the coffee free periods (coffee abstention) and the difference between measurements at the beginning and at the end of the four weeks of coffee consumption (Figure <xref ref-type="fig" rid="F1">1</xref>). Trial duration of 3&#x02013;4 weeks has previously been shown to be sufficient to get an effect of coffee on serum cholesterol [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B23">23</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Study design</p></caption><graphic xlink:href="1476-511X-3-26-1"/></fig></sec><sec><title>Subjects and procedure</title><p>Participants were recruited by advertising in Gothenburg's major newspaper. Inclusion criteria were age-range 30&#x02013;65 years, free from clinically recognized chronic diseases, such as cardiovascular diseases, cancer, renal disorders, liver disease and diabetes mellitus. The participants were required to be free from anti-epileptic or cholesterol lowering drugs, and had been using coffee on a regular basis for at least five years and were currently non-smokers (at least for the last six months).</p><p>During the coffee drinking periods the participants were instructed to drink about 600 mL filter brewed coffee/day (4 cups), according to standardised measures. The coffee was provided to guarantee that they were all exposed to the same brand and quality of filter brewed coffee. All participants also got the same kind of standardised coffee filter and measuring spoon.</p><p>The coffee filters used were of the brand Euro-Shopper, made by Indupa N.V., Zaventem, Belgium. Divergence from the 4 cups was reported. The participants were allowed to drink tea and other caffeine containing beverages during the coffee-free periods.</p></sec><sec><title>Effect variables</title><p>Non-fasting blood samples were drawn at inclusion and at three, seven, ten and fourteen weeks after start of the study. Prior to analysis, prepared serum was stored at -70&#x000b0;C.</p><p>The blood samples were analysed for blood lipids (total cholesterol, HDL cholesterol, triglycerides, lipoprotein(a) (Lp(a)) and urate in serum. Serum cholesterol and triglycerides were determined by an enzymatic procedure on a Hitachi 917 analyzer. HDL cholesterol was determined enzymatically after precipitation of VLDL, LDL and chylomicrones by &#x003b1;-cyklodextrinsulphate and dextransulphate. Determination of Lp(a) was done by the method Tint Elize Lp(a) of Biopool International. Serum urate was analysed by Hitachi 917 autoanalyser. Body Mass Index (BMI; kg/m<sup>2</sup>) was recorded once during the study. Blood pressure was recorded by manual device and EKG and heart rate were recorded at all five visits.</p><p>The dietary habits were assessed by dietary frequency questionnaires at the beginning of the study. A follow-up survey with special emphasis on changes in food habits during the four different periods was undertaken. The dietary questionnaire was based upon a Norwegian version, which has been used in a number of previous studies [<xref ref-type="bibr" rid="B24">24</xref>].</p></sec><sec><title>Genotype Analysis</title><p><italic>APOE </italic>genotypes were determined by solid-phase minisequencing as previously described by Blennow et al [<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Statistical methods</title><p>All analyses were performed using the SAS<sup>&#x000a9;</sup>software version 8. Signed rank test was used to test differences in the groups. Wilcoxon rank sum test was used to test differences at baseline and differences between the groups. The mean was used as location measure and measures of variation were described in terms of standard deviation. P-values &#x0003c; 0.05 were considered statistically significant.</p></sec></sec><sec><title>Results</title><p>A total of 156 persons responded to the advertisement and of these 124 fulfilled the criteria and were able to take part. Three persons decided to withdraw during the study, leaving a total of 121 participants. One person was not able to take part during the first two periods and five persons were not able to take part in the last two periods, which resulted in 120 participants in the first trial period and 116 in the subsequent trial period.</p><sec><title>Genotype frequencies</title><p>The <italic>APOE </italic>allele frequencies were 6.1% for the &#x003b5;2 allele, 75.6% for the &#x003b5;3 allele and 18.2% for the &#x003b5;4 allele. This distribution agrees well with those reported in other populations in northern Europe [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Genotype and allele frequencies for the <italic>APOE </italic>polymorphism are given in Table <xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><italic>APOE </italic>genotype and allele frequency, n = 121</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left">n</td><td align="left">%</td></tr></thead><tbody><tr><td align="left"><italic>&#x003b5;2/&#x003b5;2</italic></td><td align="left">2</td><td align="left">1.7</td></tr><tr><td align="left"><italic>&#x003b5;2/&#x003b5;3</italic></td><td align="left">9</td><td align="left">7.4</td></tr><tr><td align="left"><italic>&#x003b5;2/&#x003b5;4</italic></td><td align="left">2</td><td align="left">1.7</td></tr><tr><td align="left"><italic>&#x003b5;3/&#x003b5;3</italic></td><td align="left">69</td><td align="left">57.0</td></tr><tr><td align="left"><italic>&#x003b5;3/&#x003b5;4</italic></td><td align="left">36</td><td align="left">29.8</td></tr><tr><td align="left"><italic>&#x003b5;4/&#x003b5;4</italic></td><td align="left">3</td><td align="left">2.5</td></tr><tr><td align="left"><italic>&#x003b5;2</italic></td><td align="left">15</td><td align="left">6.2</td></tr><tr><td align="left"><italic>&#x003b5;3</italic></td><td align="left">183</td><td align="left">75.6</td></tr><tr><td align="left"><italic>&#x003b5;4</italic></td><td align="left">44</td><td align="left">18.2</td></tr></tbody></table></table-wrap></sec><sec><title>Serum cholesterol concentrations according to genotype and coffee exposure</title><p>Individual <italic>APOE </italic>genotypes (six subgroups, Table <xref ref-type="table" rid="T1">1</xref>) did not influence baseline values or coffee-induced changes in serum cholesterol, serum HDL cholesterol, serum triglycerides or serum Lp(a), possibly due to a small sample size (data not shown). &#x003b5;4-positive individuals had similar serum cholesterol levels and coffee-induced changes in cholesterol concentration as &#x003b5;4-negative individuals (data not shown). However, when grouping <italic>&#x003b5;2</italic>-positive individuals it was revealed that these displayed significantly lower cholesterol at baseline (Table <xref ref-type="table" rid="T2">2</xref>). There was a significant difference in cholesterol decrease between week 0 and 3 for both groups. There was no difference between the two groups regarding the cholesterol decrease in the first coffee abstention period but there was a significant difference in cholesterol decrease in the second coffee abstention period, where &#x003b5;<italic>2</italic>-negative individuals displayed a larger decrease in cholesterol (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Serum cholesterol concentration (mmol/L) at baseline and after two 3-week periods of coffee abstention (week 0 &#x02013; 3 and week 7 &#x02013; 10) for <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive (n = 13) and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative (n = 108) individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold><italic>APOE &#x003b5;2</italic>-positive</bold></td><td align="left"><bold><italic>APOE </italic>&#x003b5;<italic>2</italic>-negative</bold></td><td align="left"><bold>p</bold></td></tr><tr><td></td><td align="left">n = 13</td><td align="left">n = 107/103 <sup>a</sup></td><td></td></tr></thead><tbody><tr><td align="left"><italic>First trial period</italic></td><td></td><td></td><td></td></tr><tr><td align="left">week 0</td><td align="left">4.68 (0.80)</td><td align="left">5.28 (0.93)</td><td align="left">0.01<sup>b</sup></td></tr><tr><td align="left">week 3</td><td align="left">4.49 (0.71)</td><td align="left">5.05 (0.90)</td><td></td></tr><tr><td align="left">diff week 0&#x02013;3</td><td align="left">-0.18 (0.24)</td><td align="left">-0.23 (0.55)</td><td align="left">0.30 <sup>c</sup></td></tr><tr><td align="left">p (diff 0&#x02013;3)</td><td align="left">0.02 <sup>d</sup></td><td align="left">&#x0003c;0.0001<sup>d</sup></td><td></td></tr><tr><td align="left"><italic>Second trial period</italic></td><td></td><td></td><td></td></tr><tr><td align="left">week 7</td><td align="left">4.52 (0.71)</td><td align="left">5.34 (0.93)</td><td></td></tr><tr><td align="left">week 10</td><td align="left">4.34 (0.64)</td><td align="left">4.95 (0.89)</td><td></td></tr><tr><td align="left">week 7&#x02013;10</td><td align="left">-0.18 (0.41)</td><td align="left">-0.39 (0.55)</td><td align="left">0.08 <sup>c</sup></td></tr><tr><td align="left">p (diff 7&#x02013;10)</td><td align="left">0.13</td><td align="left">&#x0003c;0.0001<sup>d</sup></td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>107 participants in the first trial period and 103 participants in the second trial period</p><p><sup>b </sup>Significant difference between <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative at baseline, Wilcoxon rank sum test</p><p><sup>c </sup>No significant difference between <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative in differences between week 0&#x02013;3 or week 7&#x02013;10, Wilcoxon rank sum test</p><p><sup>d </sup>Significant difference between week 0&#x02013;3 for the <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive group and between week 0&#x02013;3 and week 7&#x02013;10 for the <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative group, Signed rank test</p></table-wrap-foot></table-wrap><p>Coffee consumption resulted in a significant cholesterol increase in the &#x003b5;<italic>2</italic>-negative group in both trial periods (w 3&#x02013;7 and w 10&#x02013;14), but not in the &#x003b5;<italic>2</italic>-positive group (Table <xref ref-type="table" rid="T3">3</xref>). There were no differences between the &#x003b5;<italic>2</italic>-positive and the &#x003b5;<italic>2</italic>-negative group according to baseline characteristics as sex, age, body mass index (BMI) and coffee consumption prior to the study (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Serum cholesterol concentration (mmol/L) after two 4-week periods of coffee consumption (week 3 &#x02013; 7 and week 10 &#x02013; 14) for <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive (n = 13) and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative (n = 108) individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><italic>APOE </italic>&#x003b5;<italic>2</italic>-positive</td><td align="left"><italic>APOE </italic>&#x003b5;<italic>2</italic>-negative</td><td align="left">p</td></tr><tr><td></td><td align="left">n = 13</td><td align="left">n = 107/103 <sup>a</sup></td><td></td></tr></thead><tbody><tr><td align="left"><italic>First trial period</italic></td><td></td><td></td><td></td></tr><tr><td align="left">week 3</td><td align="left">4.49 (0.71)</td><td align="left">5.05 (0.90)</td><td></td></tr><tr><td align="left">week 7</td><td align="left">4.52 (0.71)</td><td align="left">5.34 (0.93)</td><td></td></tr><tr><td align="left">diff week 3&#x02013;7</td><td align="left">0.03 (0.57)</td><td align="left">0.29 (0.57)</td><td align="left">0.09 <sup>b</sup></td></tr><tr><td align="left">p (diff 3&#x02013;7)</td><td align="left">0.70</td><td align="left">&#x0003c;0.0001 <sup>c</sup></td><td></td></tr><tr><td align="left"><italic>Second trial period</italic></td><td></td><td></td><td></td></tr><tr><td align="left">week 10</td><td align="left">4.34 (0.64)</td><td align="left">4.95 (0.89)</td><td></td></tr><tr><td align="left">week 14</td><td align="left">4.54 (0.84)</td><td align="left">5.09 (0.85)</td><td></td></tr><tr><td align="left">diff week 10&#x02013;14</td><td align="left">0.20 (0.47)</td><td align="left">0.14 (0.59)</td><td align="left">0.37 <sup>b</sup></td></tr><tr><td align="left">p (diff 10&#x02013;14)</td><td align="left">0.15</td><td align="left">0.009 <sup>c</sup></td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>107 participants in the first trial period and 103 participants in the second trial period</p><p><sup>b </sup>No significant difference between 2-positive and 2-negative in differences between week 3&#x02013;7 or week 10&#x02013;14, Wilcoxon rank sum test</p><p><sup>c </sup>Significant difference between week 0&#x02013;3 and week 7&#x02013;10 for the <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative group, Signed rank test</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Baseline characteristics for <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive (n = 13) and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative (n = 108) individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><italic>APOE </italic>&#x003b5;<italic>2</italic>-positive</td><td align="left"><italic>APOE </italic>&#x003b5;<italic>2</italic>-negative</td><td align="left">p</td></tr><tr><td></td><td align="left">n = 13</td><td align="left">n = 108</td><td></td></tr></thead><tbody><tr><td align="left">Sex (% women)</td><td align="left">77</td><td align="left">79</td><td align="left">ns <sup>a</sup></td></tr><tr><td align="left">Age (years)</td><td align="left">46.6</td><td align="left">48.7</td><td align="left">0.44 <sup>b</sup></td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">25.7</td><td align="left">25.8</td><td align="left">0.87 <sup>b</sup></td></tr><tr><td align="left">Coffee consumption (cups/day)</td><td align="left">4.3</td><td align="left">3.7</td><td align="left">0.12 <sup>b</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>No significant difference between <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative at baseline, Chi square test</p><p><sup>b </sup>No significant difference between <italic>APOE </italic>&#x003b5;<italic>2</italic>-positive and <italic>APOE </italic>&#x003b5;<italic>2</italic>-negative at baseline, Wilcoxon rank sum test</p></table-wrap-foot></table-wrap></sec><sec><title>Dietary monitoring and compliance</title><p>The dietary survey did not reveal any important changes during the four intervention periods [<xref ref-type="bibr" rid="B22">22</xref>]. Coffee consumption or non-compliance was reported by six persons during the first coffee abstention period (mean 1.8 cups/period), whereas four persons reported coffee consumption in the second coffee abstention period (mean 0.7 cups/period).</p></sec></sec><sec><title>Discussion</title><p>Subjects with different <italic>APOE </italic>genotypes differ in the absorption efficiency of cholesterol from the intestine, in the synthesis rates of cholesterol and bile acids, and in the production of LDL apoprotein B [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. This suggests that the response of serum cholesterol to diet may be affected by the <italic>APOE e2/e3/e4 </italic>polymorphism [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. One previous study examined the effect of purified cafestol on serum lipids in relation to the <italic>APOE </italic>polymorphism [<xref ref-type="bibr" rid="B26">26</xref>] and found that responses of LDL-cholesterol to cafestol were slightly smaller among carriers of the <italic>APOE </italic>&#x003b5;4 allele. Here, we investigate for the first time the possible influence of the <italic>APOE </italic>polymorphism on the cholesterol-raising effect of filtered coffee.</p><p><italic>APOE </italic>&#x003b5;4-positive individuals did not differ significantly from &#x003b5;4-negative individuals with regard to baseline cholesterol concentration or coffee-induced changes in cholesterol concentration. However, we confirm that &#x003b5;2-positive individuals display significantly lower cholesterol levels at baseline than &#x003b5;2-negative individuals. A tendency was seen that <italic>&#x003b5;2</italic>-positive individuals might be partly protected from the cholesterol increasing effect of coffee consumption. This was, however, only seen in the first trial period and will require further investigations. In conclusion, the <italic>APOE &#x003b5;2</italic>/<italic>&#x003b5;3</italic>/<italic>&#x003b5;4 </italic>polymorphism is not a strong modulator of the cholesterol-increasing effect of coffee. Other genes should be discussed and further investigation is needed to see if there is a genetic factor in the cholesterol-raising effect of coffee.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from the Swedish Medical Research Council (project #12103), the Sahlgrenska University Hospital and the Swedish Council for Working Life and Social Research.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>T</given-names></name><name><surname>Yamakawa-Kobayashi</surname><given-names>K</given-names></name><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Amemiya</surname><given-names>H</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Kawata</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Noguchi</surname><given-names>Y</given-names></name><name><surname>Sugishita</surname><given-names>Y</given-names></name><name><surname>Hamaguchi</surname><given-names>H</given-names></name></person-group><article-title>Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study</article-title><source>Atherosclerosis</source><year>1998</year><volume>137</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">9568733</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(97)00244-X</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davignon</surname><given-names>J</given-names></name><name><surname>Gregg</surname><given-names>RE</given-names></name><name><surname>Sing</surname><given-names>CF</given-names></name></person-group><article-title>Apolipoprotein E polymorphism and atherosclerosis</article-title><source>Arteriosclerosis</source><year>1988</year><volume>8</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">3277611</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eichner</surname><given-names>JE</given-names></name><name><surname>Dunn</surname><given-names>ST</given-names></name><name><surname>Perveen</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>DM</given-names></name><name><surname>Stewart</surname><given-names>KE</given-names></name><name><surname>Stroehla</surname><given-names>BC</given-names></name></person-group><article-title>Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review</article-title><source>Am J Epidemiol</source><year>2002</year><volume>155</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">11882522</pub-id><pub-id pub-id-type="doi">10.1093/aje/155.6.487</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahley</surname><given-names>RW</given-names></name><name><surname>Rall</surname><given-names>SC</given-names></name></person-group><article-title>APOLIPOPROTEIN E: Far More Than a Lipid Transport Protein</article-title><source>Annu Rev Genomics Hum Genet</source><year>2000</year><volume>1</volume><fpage>507</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">11701639</pub-id><pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.507</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease</article-title><source>Ann Intern Med</source><year>2004</year><volume>141</volume><fpage>137</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15262670</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tammi</surname><given-names>A</given-names></name><name><surname>R&#x000f6;nnemaa</surname><given-names>T</given-names></name><name><surname>Rask-Nissil&#x000e4;</surname><given-names>L</given-names></name><name><surname>Miettinen</surname><given-names>TA</given-names></name><name><surname>Gylling</surname><given-names>H</given-names></name><name><surname>Valsta</surname><given-names>L</given-names></name><name><surname>Viikari</surname><given-names>J</given-names></name><name><surname>V&#x000e4;lim&#x000e4;ki</surname><given-names>I</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name></person-group><article-title>Apolipoprotein E Phenotype Regulates Cholesterol Absorption in Healthy 13-Month-Old Children-The STRIP Study</article-title><source>Pediatr Res</source><year>2001</year><volume>50</volume><fpage>688</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">11726725</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tammi</surname><given-names>A</given-names></name><name><surname>R&#x000f6;nnemaa</surname><given-names>T</given-names></name><name><surname>Viikari</surname><given-names>J</given-names></name><name><surname>Jokinen</surname><given-names>E</given-names></name><name><surname>Lapinleimu</surname><given-names>H</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name></person-group><article-title>Apolipoprotein E4 phenotype increases non-fasting serum triglyceride concentration in infants &#x02013; the STRIP study</article-title><source>Atherosclerosis</source><year>2000</year><volume>152</volume><fpage>135</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">10996348</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(99)00436-0</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steng&#x000e5;rd</surname><given-names>JH</given-names></name><name><surname>Pekkanen</surname><given-names>J</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Nissinen</surname><given-names>A</given-names></name><name><surname>Sing</surname><given-names>CF</given-names></name></person-group><article-title>Genotypes with the apolipoprotein &#x003b5;4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men</article-title><source>Hum Genet</source><year>1996</year><volume>97</volume><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">8655152</pub-id><pub-id pub-id-type="doi">10.1007/s004390050115</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ilveskoski</surname><given-names>E</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Lehtim&#x000e4;ki</surname><given-names>T</given-names></name><name><surname>Laippala</surname><given-names>P</given-names></name><name><surname>Savolainen</surname><given-names>V</given-names></name><name><surname>Pajarinen</surname><given-names>J</given-names></name><name><surname>Penttil&#x000e4;</surname><given-names>A</given-names></name><name><surname>Lalu</surname><given-names>KH</given-names></name><name><surname>M&#x000e4;nnikk&#x000f6;</surname><given-names>A</given-names></name><name><surname>Liesto</surname><given-names>KK</given-names></name><name><surname>Koivula</surname><given-names>T</given-names></name><name><surname>Karhunen</surname><given-names>PJ</given-names></name></person-group><article-title>Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men. An autopsy study</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">10441097</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corbo</surname><given-names>RM</given-names></name><name><surname>Scacchi</surname><given-names>R</given-names></name><name><surname>Vilardo</surname><given-names>T</given-names></name><name><surname>Ruggeri</surname><given-names>M</given-names></name></person-group><article-title>Polymorphisms in the Apolipoprotein E gene regulatory region in relation to coronary heart disease and their effect on plasma Apolipoprotein E</article-title><source>Clin Chem Lab Med</source><year>2001</year><volume>39</volume><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11256794</pub-id><pub-id pub-id-type="doi">10.1515/CCLM.2001.002</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Breslow</surname><given-names>JL</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name></person-group><article-title>A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men</article-title><source>Atherosclerosis</source><year>2003</year><volume>166</volume><fpage>323</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12535745</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(02)00335-0</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steng&#x000e5;rd</surname><given-names>JH</given-names></name><name><surname>Weiss</surname><given-names>KM</given-names></name><name><surname>Sing</surname><given-names>CF</given-names></name></person-group><article-title>An ecological study of association between coronary heart disease mortality rates in men and the relative frequencies of common allelic variations in the gene coding for apolipoprotein E</article-title><source>Hum Genet</source><year>1998</year><volume>103</volume><fpage>234</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">9760210</pub-id><pub-id pub-id-type="doi">10.1007/s004390050811</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerdes</surname><given-names>LU</given-names></name><name><surname>Gerdes</surname><given-names>C</given-names></name><name><surname>Kervinen</surname><given-names>K</given-names></name><name><surname>Savolainen</surname><given-names>M</given-names></name><name><surname>Klausen</surname><given-names>IC</given-names></name><name><surname>Hansen</surname><given-names>PS</given-names></name><name><surname>Kesaniemi</surname><given-names>YA</given-names></name><name><surname>Faergeman</surname><given-names>O</given-names></name></person-group><article-title>The apolipoprotein <inline-graphic xlink:href="1476-511X-3-26-i1.gif"/> allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. A substudy of the Scandinavian Simvastatin Survival Study</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>1366</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10736278</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corder</surname><given-names>EH</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Strittmatter</surname><given-names>WJ</given-names></name><name><surname>Schmechel</surname><given-names>DE</given-names></name><name><surname>Gaskell</surname><given-names>PC</given-names></name><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>921</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">8346443</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>J</given-names></name><name><surname>Davignon</surname><given-names>J</given-names></name><name><surname>Bouthillier</surname><given-names>D</given-names></name><name><surname>Kogan</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>P</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name></person-group><article-title>Apolipoprotein E polymorphism and Alzheimer's disease</article-title><source>Lancet</source><year>1993</year><volume>342</volume><fpage>697</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">8103819</pub-id><pub-id pub-id-type="doi">10.1016/0140-6736(93)91705-Q</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strittmatter</surname><given-names>WJ</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Schmechel</surname><given-names>D</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Enghild</surname><given-names>J</given-names></name><name><surname>Salvesen</surname><given-names>GS</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name></person-group><article-title>Apolipoprotein E: high-avidity binding to &#x003b2;-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1977</fpage><lpage>1981</lpage><pub-id pub-id-type="pmid">8446617</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urgert</surname><given-names>R</given-names></name><name><surname>Katan</surname><given-names>B</given-names></name></person-group><article-title>The cholesterol-raising factor from coffee beans</article-title><source>Annu Rev Nutr</source><year>1997</year><volume>17</volume><fpage>305</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">9240930</pub-id><pub-id pub-id-type="doi">10.1146/annurev.nutr.17.1.305</pub-id></citation></ref><ref id="B18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Bak</surname><given-names>A</given-names></name></person-group><article-title>Coffee and cardiovascular risk; an epidemiological study</article-title><source>PhD thesis</source><year>1990</year><publisher-name>Erasmus Univerisity Rotterdam</publisher-name></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahola</surname><given-names>I</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Aro</surname><given-names>A</given-names></name></person-group><article-title>The hypercholesterolaemic factor of boiled coffee is retained by a paper filter</article-title><source>J Inter Med</source><year>1991</year><volume>230</volume><fpage>293</fpage><lpage>297</lpage></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Dusseldorp</surname><given-names>M</given-names></name><name><surname>Katan</surname><given-names>MB</given-names></name><name><surname>Van Vliet</surname><given-names>T</given-names></name><name><surname>Demacker</surname><given-names>PNM</given-names></name><name><surname>Stalenhoef</surname><given-names>A</given-names></name></person-group><article-title>Cholesterol-raising factor from boiled coffee does not pass a paper filter</article-title><source>Arterioscler Thromb</source><year>1991</year><volume>11</volume><fpage>586</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">2029499</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>B</given-names></name><name><surname>Mosd&#x000f8;l</surname><given-names>A</given-names></name><name><surname>Retterst&#x000f8;l</surname><given-names>L</given-names></name><name><surname>Landaas</surname><given-names>S</given-names></name><name><surname>Thelle</surname><given-names>DS</given-names></name></person-group><article-title>Abstention from filtered coffee reduces the levels of homocysteine and cholesterol &#x02013; a randomized, controlled trial</article-title><source>Am J Clin Nutr</source><year>2001</year><volume>74</volume><fpage>302</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">11522552</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strandhagen</surname><given-names>E</given-names></name><name><surname>Thelle</surname><given-names>DS</given-names></name></person-group><article-title>Filtered coffee raises serum cholesterol: results from a controlled study</article-title><source>Eur J Clin Nutr</source><year>2003</year><volume>57</volume><fpage>1164</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">12947437</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejcn.1601668</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grubben</surname><given-names>MJ</given-names></name><name><surname>Boers</surname><given-names>GH</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name><name><surname>Broekhuizen</surname><given-names>R</given-names></name><name><surname>de Jong</surname><given-names>R</given-names></name><name><surname>van Rijt</surname><given-names>L</given-names></name><name><surname>de Ruijter</surname><given-names>E</given-names></name><name><surname>Swinkels</surname><given-names>DW</given-names></name><name><surname>Nagengast</surname><given-names>FM</given-names></name><name><surname>Katan</surname><given-names>MB</given-names></name></person-group><article-title>Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers: a randomized trial</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>71</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">10648261</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nes</surname><given-names>M</given-names></name><name><surname>Frost Andersen</surname><given-names>L</given-names></name><name><surname>Solvoll</surname><given-names>K</given-names></name><name><surname>Sandstad</surname><given-names>B</given-names></name><name><surname>Hustvedt</surname><given-names>BE</given-names></name><name><surname>L&#x000f8;v&#x000f8;</surname><given-names>A</given-names></name><name><surname>Drevon</surname><given-names>C</given-names></name></person-group><article-title>Accuracy of a quantitative food frequency questionnaire applied in elderly Norwegian women</article-title><source>Eur J Clin Nutr</source><year>1992</year><volume>46</volume><fpage>809</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">1425535</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Ricksten</surname><given-names>A</given-names></name><name><surname>Prince</surname><given-names>JA</given-names></name><name><surname>Brookes</surname><given-names>AJ</given-names></name><name><surname>Emahazion</surname><given-names>T</given-names></name><name><surname>Wasslavik</surname><given-names>C</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Batsman</surname><given-names>S</given-names></name><name><surname>Marcusson</surname><given-names>J</given-names></name><name><surname>Nagga</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Regland</surname><given-names>B</given-names></name><name><surname>Olofsson</surname><given-names>H</given-names></name><name><surname>Hesse</surname><given-names>C</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Jansson</surname><given-names>A</given-names></name><name><surname>Palmqvist</surname><given-names>L</given-names></name><name><surname>Rymo</surname><given-names>L</given-names></name></person-group><article-title>No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression</article-title><source>J Neural Transm</source><year>2000</year><volume>107</volume><fpage>1065</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11041282</pub-id><pub-id pub-id-type="doi">10.1007/s007020070052</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weggemans</surname><given-names>RM</given-names></name><name><surname>Zock</surname><given-names>PL</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Pedro-Botet</surname><given-names>J</given-names></name><name><surname>Katan</surname><given-names>MB</given-names></name></person-group><article-title>Apoprotein E genotype and the response of serum cholesterol to dietary fat, cholesterol and cafestol</article-title><source>Atherosclerosis</source><year>2001</year><volume>154</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">11257255</pub-id><pub-id pub-id-type="doi">10.1016/S0021-9150(00)00720-6</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>LF</given-names></name><name><surname>McNeill</surname><given-names>G</given-names></name><name><surname>Avenell</surname><given-names>A</given-names></name></person-group><article-title>Genetic variation and the lipid response to dietary intervention: a systematic review</article-title><source>Am J Clin Nutr</source><year>2003</year><volume>77;</volume><fpage>1098</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">12716659</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ordovas</surname><given-names>JM</given-names></name></person-group><article-title>Gene-diet interaction and plasma lipid responses to dietary intervention</article-title><source>Biochem Soc Trans</source><year>2002</year><volume>30</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">12023827</pub-id><pub-id pub-id-type="doi">10.1042/0300-5127:0300068</pub-id></citation></ref></ref-list></back></article> 